Molecular Insight Pharmaceuticals (MIP) has executed a 10-year agreement to supply the Onalta 90-Y edotreotide radiotherapeutic to BioMedica Life Sciences in Athens, Greece.
Onalta is a new radiotherapeutic product candidate under development for the treatment of metastatic carcinoid and pancreatic neuroendocrine tumors in patients whose symptoms are not controlled by conventional therapy, according to the Cambridge, Mass.-based MIP.
The firm said it entered into a territory license agreement with BioMedica for commercialization of Onalta in certain European countries, the Middle East, North Africa, Russia and Turkey. The company still retains Onalta rights in all other markets and territories, including the United States, Japan and Asia.
Last week, MIP also entered into a contract manufacturing agreement for ten years with Berlin-based Eckert & Ziegler to manufacture and supply Onalta for registration clinical trials within the BioMedica territories.